Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Purpose To assess vision, injection quantity, initial lesion size, and final anatomic status in patients with nAMD completing the treat-extend-stop (TES) protocol.Methods Patients with nAMD received ≥ 3 monthly anti-VEGF injections followed by 1-2 week injection interval extensions, with intra/subretinal fluid resolution on SD-OCT, to 12 weeks. With quiescent disease, and 2 quarterly injections, patients were monitored alone beginning at 4 weeks extending by 1-2 week intervals until quarterly monitoring.Results Eighty-eight of 143 eyes with nAMD completed the TES protocol without disease recurrence. Sixteen (18.2%) developed sub-foveal geographic atrophy (GA), 25 (28.4%) developed fibrovascular scarring (FV) and 47 (53.4%) developed regressed choroidal neovascularization (rCNV) with 16.9 ± 13.3 average injections between the 3 groups which was not statistically significant. Average treatment time was 30.3 ± 26.1 months and subsequent follow-up was 23.2 ± 19.8 months. Average lesion size for FV was 18.77 ± 10.8mm 2 vs. GA at 12.00 ± 9.99mm 2 vs. regressed CNV at 7.12 ± 6.5mm 2 (p < 0.05). Pre, post, and final vision for GA was 39.6 letters (20/160) vs. 32.7 letters (20/200 + 2, p = 0.4725) vs. 25.0 letters (20/320, p = 0.0865); FV was 22.4 letters (20/400 + 2) vs. 11.6 letters (20/640, p = 0.0351) vs. 11.0 letters (20/640 + 1, p = 0.0226), and rCNV was 56.4 letters (20/80 + 1) vs. 69.5 letters (20/40, p < 0.001) vs. 67.3 letters (20/40-2, p = 0.0016). In the rCNV group, 17/46 eyes gained ≥ 3 lines and 30/46 eyes achieved ≥ 20/40 vision. Non-central GA expanded 0.226 ± 0.126 mm vs. 0.225 ± 0.098 mm during and after treatment completion over 24 months (p = 0.99).Conclusions Central GA or FV portends worse visual outcomes vs. rCNV after cessation of therapy. Anti-VEGF therapy may not affect the rate of GA expansion. Final anatomic character and location are key determinants of final vision.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been reported that some patients with nAMD do not require further treatment after discontinuation of anti-VEGF injections, therefore without a control arm we are unable to definitively conclude that participants in this study would have required additional therapy after ceasing standard-of-care injections.30,31”
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485 · cited 2×
“Some RCT excluded lesions greater than 30mm2 [2, 3, 8].”
BackgroundRanibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Martin, D. F., Maguire, M. G., Fine, S. L., Ying, G.-S., Jaffe, G. J., Grunwald, J. E., Toth, C., Redford, M., & Ferris, F. L. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.03.053 · Cited by 1,715 · cited 2×
“The CATT studies demonstrated a 21% increase in GA to 41% from years 2–5, with higher injection frequencies associated with greater GA throughout all years, although it was not statistically significant at year 5 [4, 10, 26].”
BackgroundMethodAge-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Brown, D. M., Michels, M., Kaiser, P. K., Heier, J. S., Sy, J. P., & Ianchulev, T. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2008.10.018 · Cited by 1,318 · cited 3×
“Some RCT excluded lesions greater than 30mm2 [2, 3, 8].”
BackgroundSeven-Year Outcomes in Ranibizumab-Treated Patients in ANCHOR, MARINA, and HORIZON
Rofagha, S., Bhisitkul, R. B., Boyer, D. S., Sadda, S. R., & Zhang, K. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2013.03.046 · Cited by 1,023 · cited 3×
“Likewise, central macular atrophy was associated with worse BCVA in the SEVENUP study [5].”
BackgroundChakravarthy, U., Harding, S. P., Rogers, C. A., Downes, S. M., Lotery, A. J., Culliford, L. A., & Reeves, B. C. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61501-9 · Cited by 748 · cited 1×
“The third and most common strategy is the treat-and-extend regimen (TAE), with its variant the treat-extend-stop (TES) method which we previously described [6, 13, 14].”
BackgroundMaguire, M. G., Martin, D. F., Ying, G.-S., Jaffe, G. J., Daniel, E., Grunwald, J. E., Toth, C. A., Ferris, F. L., & Fine, S. L. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.03.045 · Cited by 708 · cited 11×
“Subretinal and intraretinal fluid was evaluated using SD-OCT.”
BackgroundMethodInfluentialHo, A. C., Busbee, B. G., Regillo, C. D., Wieland, M. R., Van Everen, S. A., Li, Z., Rubio, R. G., & Lai, P. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2014.05.009 · Cited by 590 · cited 1×
“Although fixed monthly dosing and TAE methods, and variations, have demonstrated the greatest visual improvement in short and long-term studies, they have achieved these outcomes typically with higher injection quantity [9, 15, 16].”
BackgroundBusbee, B. G., Ho, A. C., Brown, D. M., Heier, J. S., Suñer, I. J., Li, Z., Rubio, R. G., & Lai, P. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.10.014 · Cited by 500 · cited 2×
“Although fixed monthly dosing and TAE methods, and variations, have demonstrated the greatest visual improvement in short and long-term studies, they have achieved these outcomes typically with higher injection quantity [9, 15, 16].”
Background
Cited by
Khanani, A. M., Boyer, D. S., Wykoff, C. C., Regillo, C. D., Busbee, B. G., Pieramici, D., Danzig, C. J., Joondeph, B. C., Major, J. C., Turpcu, A., et al. (2024) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102394 · Cited by 76
“30,31 Due to the small sample size of each cohort, the effectiveness of the two corticosteroid regimens could not be compared.”
BackgroundManagement of fibrosis in neovascular age-related macular degeneration
Chakravarthy, U., Foss, A. J. E., Panos, G. D., Pető, T., Rotsos, T., Sadda, S. R., Cock, E. D., & Empeslidis, T. (2025) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-025-06890-x · Cited by 4
Adrean, S. D., Knight, D. K., Chaili, S., Ramkumar, H. L., Pirouz, A., & Grant, S. (2022) · International Journal of Retina and Vitreous · doi:10.1186/s40942-022-00361-9 · Cited by 2
“Baseline vision for that study was 20/125 and final vision at end of treatment was 20/125 with an average treatment time of 30 months [22].”
BackgroundSelf-citationChujo, S., Matsubara, H., Matsui, Y., Sugimoto, M., & Kondo, M. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113659 · Cited by 1
“of anti-VEGF may not be the primary cause of the expansion of RPE atrophy, with which our findings are in agreement [35].”
BackgroundResultGaray‐Aramburu, G., Rodríguez-Feijoo, D., Aldazabal-Echeveste, M., Barrio, Z. D., Eiras-Fernández, A., Pinero, D. P., & Larrauri-Arana, A. (2023) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2023.02.021 · Cited by 1
Metadata
- Authors
- Adrean, S. D., Chaili, S., Pirouz, A., & Grant, S.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Adrean, Sean D.
- Venue
- Graefe's Archive for Clinical and Experimental Ophthalmology
- Published
- 2021-07-12
- Volume
- 259
- Issue
- 12
- Pages
- 3665-3673
- ISSN
- 0721-832X (ISSN-L)
- 1435-702X
- OpenAlex
- W3182777314
- Cited by
- 8
- References
- 33
- Citations by year
- 2026: 1 · 2025: 2 · 2023: 3 · 2022: 2
- FWCI
- 1.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Graefe s Archive for Clinical and Experimental Ophthalmology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- neovascular age-related macular degeneration, anti-VEGF therapy, geographic atrophy, recurrence, treatment duration, visual acuity outcomes, lesion size, patient-reported outcomes, quality of life
- MeSH terms
- Ranibizumab, Humans, Macular Degeneration, Visual Acuity, Treatment Outcome, Choroidal Neovascularization, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Wet Macular Degeneration, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. https://app.cochat.ai/papers/10.1007/s00417-021-05283-0
- The paper
- Adrean, S. D., Chaili, S., Pirouz, A., & Grant, S. (2021). Results of patients with neovascular age-related macular degeneration managed by a treat-extend-stop protocol without recurrence. Graefe's Archive for Clinical and Experimental Ophthalmology. https://doi.org/10.1007/s00417-021-05283-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.